[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599120":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":10,"responsibleParty":26,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":10,"enrollmentInfo":38,"targetDuration":41,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":10,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Shanghai 10th People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Isavuconazole group",null,"Critically ill patients who meet the indicated conditions per the prescribing information, administer isavuconazole as follows: Loading dose: 200 mg every 8 hours (q8h) for three times, Maintenance dose: 200 mg once daily (qd)",[13],"Drug: Isavuconazole treatment",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Isavuconazole treatment","Administer isavuconazole as follows: Loading dose: 200 mg every 8 hours (q8h) for three times, Maintenance dose: 200 mg once daily (qd)",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Wen-Xiang Cao","CONTACT","+8613062772669","731438603@qq.com",{"type":27,"investigatorFullName":22,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Senior Clinical Pharmacist","100599120","isavuconazole-in-critically-ill-patients-efficacy-and-safety-100599120",false,"NCT07080359","Isavuconazole in Critically Ill Patients: Efficacy and Safety","Isavuconazole in Critically Ill Patients: A Study on Antifungal Efficacy and Safety","Inclusion Criteria:\n\n* Adult critically ill patients (≥18 years) admitted to ICU with suspected or confirmed invasive fungal infection (IFI)\n* IFI diagnosis per EORTC\u002FMSGERC 2019 criteria\n\nExclusion Criteria:\n\n* Drug allergy\n* Inherited short QT syndrome\n* Contraindications for nasogastric\u002Foral drug delivery\n* \\\u003C18 years old","ALL","18 Years",{"count":39,"type":40},75,"ESTIMATED","3 Months","OBSERVATIONAL","Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in healthy individuals, exhibiting significant variability.\n\nThis study aims to explore the variability of isavuconazole plasma concentrations in critically ill patients and its correlation with efficacy and adverse effects. The research includes:\n\n1. The distribution and variability of isavuconazole plasma concentrations in critically ill patients;\n2. Clinical outcomes;\n3. Adverse effects.",[45,46,47],"Fungal Infection","Aspergillosis","Mucormycosis","NOT_YET_RECRUITING","2025-07-14",{"date":51,"type":52},"2025-07-23","ACTUAL",{"date":54,"type":40},"2025-08-01",{"date":56,"type":40},"2030-12-31",{"name":5,"class":6}]